Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Specialty Physicians are Poised to Embrace Biosimilars Arriving Imminently to the U.S. Market - The Food & Drug Administration is scheduled to release guidelines for the approval of biosimilars by the end of 2011
Specialty Physicians are Poised to Embrace Biosimilars Arriving Imminently to the U.S. Market

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2011/12/14 - The Food & Drug Administration is scheduled to release guidelines for the approval of biosimilars by the end of 2011.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The U.S. biosimilars market is a fast approaching reality. For example, the Patient Protection and Affordable Care Act of 2010, better known as the healthcare reform introduced by President Barack Obama, includes a provision for the establishment of a Food & Drug Administration (FDA) approval pathway for biosimilars. However, much uncertainty lies ahead, including the market potential as a function of physician adoption of biosimilars, as well as the fact that Amgen’s new Enbrel patent could delay a biosimilar version for 17 years.

New analysis from Frost & Sullivan’s (pharma.frost.com) Specialty Physicians Discuss their Opinions of the United States Biosimilars Market research includes an overview of a panel discussion with specialty physicians who are expected to be among the first users of biosimilars in the U.S. This research previews the thoughts and expectations of practitioners to gain insight into some of the major factors which could influence market uptake.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, title, telephone number, company email address, company Web site, city, state and country.

“Based on this representative sample of physicians, the overall adoption of biosimilars can be expected to experience widespread uptake,” said Frost & Sullivan Industry Manager Jennifer Brice. “This is in light of anticipated access to comparable therapeutic options at a lower cost versus high-cost biologics.”

Main factors with the potential to influence the rate and extent of uptake include cost, safety and efficacy data (including testing in specific patient populations), and reputation of the manufacturer. Biosimilars produced by companies that lack experience in developing and manufacturing biologics may be met with skepticism as opposed to companies with experience and a strong track record in the biologics sector.

“Physicians generally agreed that those companies with a solid reputation and strong track record of producing high-quality products would likely be trusted to bring a quality biosimilar product to market, regardless of geographic location,” said Frost & Sullivan Senior Industry Analyst Debbie Toscano. “Experience with biologics, as opposed to experience with generics, is key. However, many physicians will likely be skeptical of companies based in developing countries such as India or China that lack a strong reputation due to negative past experiences.”

Patients may perceive biologics, as opposed to biosimilars, as superior products simply due to their cost, as many people associate price with quality. A clear explanation of the financial advantages of developing a biosimilar, coupled with strong clinical data to support non-inferiority, may help to improve any negative perceptions of biosimilars. This positive clinical data from well-designed clinical trials may also increase the confidence level of physicians and help alleviate the concern of being forced to prescribe an inferior product. Strong clinical data will be the main driver of initial practitioner acceptance of biosimilars and biobetters.

“Potential skepticism may be overcome with the help of convincing clinical data for products from reputable companies highly experienced with biologics,” said Brice. “As positive real-world experience is gained, uptake is expected to gradually increase.”

Specialty Physicians Discuss their Opinions of the United States Biosimilars Market is part of the Pharmaceuticals & Biotechnology subscription, which also includes research in the following markets: Biosimilars and Follow-On Biologics Americas Conference: The Frost & Sullivan Perspective; Biosimilars–An Emerging Market in Europe; Strategic Analysis of the Indian Biosimilar Market; and Biobetters—Advent of a New Concept. Research included in subscriptions provides detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Specialty Physicians Discuss their Opinions of the United States Biosimilars Market / NA7B-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Specialty Physicians are Poised to Embrace Biosimilars Arriving Imminently to the U.S. Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Britni Myers - Frost.com 
210-477-8481 britni.myers[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today